Night_Owl_Biotech
Sep 28, 7:40 PM
A history of what's happend to the share prices of all 65 new commercial-stage oncology focused bios post FDA approval, back to 1/1/2013 (sorted by PDUFA date). The evidence appears overwhelming shareholder value is maximized via M&A exit, and in 90% of these cases within 2 years of FDA approval.
Studies from industry, government & academia looking at thousands of drug development programs over the last 50 years conclude only 95-98% of new cancer drugs in Phase 1 are never approved. This is probably why 95-98% of clinical-stage oncology focused bios fail. Of course there are exceptions
$NUVB ?
Common sense suggests this space is ripe for consolidation. Everyone wins, including the healthcare community at large via scale to best control costs.
$SNDX should be the poster boy for the phenomenon.
Had one invested
$1,000 in each bio 2 days post approval, the collective investment would be worth
$64,775 intra-day 9/28/26.
This is not investment advice. The data could be wrong
$IMCR $CELC $LEGN
